In life, there’s a common expression that also carries over into the dividend investing world: If it seems too good to be true, it usually is too good to be true. Oftentimes, dividend stocks with 6% or higher yields are yield traps. This means that the dividend income they provide to shareholders seems great, but it isn’t sustainable. Now and then, though, I stumble across high-yielding dividend stocks that aren’t yield traps. I believe that one such example is Pfizer (PFE). Interestingly, Pfize

Is Pfizer (NYSE:PFE) a High-Yielding Dividend Stock Worth Buying?

Pfizer's Q3 revenue surged 31.2% to $17.7 billion, exceeding expectations.
COVID-19 treatment demand significantly boosted revenue growth in Primary Care segment.
Oncology revenue grew 29.8% with new cancer treatments driving sales.
Pfizer declared $1.06 adjusted EPS, surpassing consensus of $0.61.
Cost realignment program expected to yield $4 billion in annual savings by 2024.

Is Pfizer (NYSE:PFE) a High-Yielding Dividend Stock Worth Buying?

FAQ

Why Bullish?

How important is it?

Why Short Term?

Related Companies

Related News